Compare Cytokinetics Inc (CYTK) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs VF Corp — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while VF Corp trades at $14.52 (market cap $5.65B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and VF Corp pays a 2.5% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and VF Corp for 64 Days on average.
| CYTK | VFC | |
|---|---|---|
Market Cap | $8.50B | $5.65B |
Volume | 2,395,556 | 6,542,273 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $21.55 |
52-Week Low | $54.76 | $12.62 |
Typical Hold Time | 19 Days | 64 Days |
Enterprise Value | $8.60B | $9.94B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
VFC trades at $14.53, up 0.55% with a bullish technical signal from moving averages. The company reported mixed quarterly results, beating in Q4 2025 but missing in subsequent quarters. Revenue declined from $11.8B in 2022 to $9.5B in 2025, with net losses in recent years. Analyst consensus shows 41% buy ratings with an $18.33 price target, while the stock faces execution risks from Vans brand weakness despite stronger Outdoor segment performance.
The outlook remains cautious with valuation appearing reasonable (P/E 20.84, P/S 0.6) but dependent on successful turnaround execution. Key risks include persistent Vans weakness, high debt levels, and competitive pressures. Upside potential exists if management can stabilize revenue and improve profitability, but investors face significant execution uncertainty in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
